Literature DB >> 32015986

Unique behavior of brain metastases during the treatment of nivolumab for metastatic renal cell carcinoma.

Tsunenori Kondo1,2, Hiroki Ishihara2.   

Abstract

Entities:  

Year:  2019        PMID: 32015986      PMCID: PMC6976459          DOI: 10.21037/atm.2019.12.46

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  15 in total

1.  Newly developing brain metastases during nivolumab therapy for metastatic renal cell carcinoma: A case series in two Japanese institutions.

Authors:  Hiroki Ishihara; Tsunenori Kondo; Toshio Takagi; Kazuhiko Yoshida; Masayoshi Okumi; Kazunari Tanabe
Journal:  Int J Urol       Date:  2019-05-21       Impact factor: 3.369

2.  Immediate Progressive Disease in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab: a Multi-Institution Retrospective Study.

Authors:  Hiroki Ishihara; Tsunenori Kondo; Toshio Takagi; Hidekazu Tachibana; Hironori Fukuda; Kazuhiko Yoshida; Junpei Iizuka; Hirohito Kobayashi; Kazunari Tanabe
Journal:  Target Oncol       Date:  2018-10       Impact factor: 4.493

3.  Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.

Authors:  Ronan Flippot; Cécile Dalban; Brigitte Laguerre; Delphine Borchiellini; Gwénaelle Gravis; Sylvie Négrier; Christine Chevreau; Florence Joly; Lionnel Geoffrois; Sylvain Ladoire; Hakim Mahammedi; Frédéric Rolland; Marine Gross-Goupil; Elise Deluche; Frank Priou; Mathieu Laramas; Philippe Barthélémy; Bérengère Narciso; Nadine Houedé; Stéphane Culine; Stéphane Oudard; Marina Chenot; Florence Tantot; Sylvie Chabaud; Bernard Escudier; Laurence Albiges
Journal:  J Clin Oncol       Date:  2019-06-13       Impact factor: 44.544

4.  Utilization of Stereotactic Radiosurgery for Renal Cell Carcinoma Brain Metastases.

Authors:  Waqar Haque; Vivek Verma; E Brian Butler; Bin S Teh
Journal:  Clin Genitourin Cancer       Date:  2018-04-03       Impact factor: 2.872

5.  Brain Metastasis From Renal-Cell Carcinoma: An Institutional Study.

Authors:  Alfredo Suarez-Sarmiento; Kevin A Nguyen; Jamil S Syed; Adam Nolte; Kamyar Ghabili; Michelle Cheng; Sandy Liu; Veronica Chiang; Harriet Kluger; Michael Hurwitz; Brian Shuch
Journal:  Clin Genitourin Cancer       Date:  2019-08-20       Impact factor: 2.872

6.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Nizar M Tannir; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K Choueiri; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Victoria Neiman; Christian K Kollmannsberger; Pamela Salman; Howard Gurney; Robert Hawkins; Alain Ravaud; Marc-Oliver Grimm; Sergio Bracarda; Carlos H Barrios; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Allen C Chen; Sabeen Mekan; M Brent McHenry; Megan Wind-Rotolo; Justin Doan; Padmanee Sharma; Hans J Hammers; Bernard Escudier
Journal:  N Engl J Med       Date:  2018-03-21       Impact factor: 91.245

7.  Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.

Authors:  Shumei Kato; Aaron Goodman; Vighnesh Walavalkar; Donald A Barkauskas; Andrew Sharabi; Razelle Kurzrock
Journal:  Clin Cancer Res       Date:  2017-03-28       Impact factor: 12.531

8.  Prognostic factors for survival in metastatic renal cell carcinoma patients with brain metastases receiving targeted therapy.

Authors:  Ibrahim Yildiz; Ahmet Bilici; Nuri Karadurmuş; Leyla Ozer; Deniz Tural; Mehmet A Kaplan; Tülay Akman; Ibrahim V Bayoglu; Mükremin Uysal; Yaşar Yildiz; Özgür Tanriverdi; Ozan Yazici; Zeki Sürmeli; Nazim Serdar Turhal; Sevil Bavbek; Fatih Selçukbiricik; Doğan Koca; Mert Basaran
Journal:  Tumori       Date:  2018-05-09       Impact factor: 2.098

9.  High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor.

Authors:  Damien Pouessel; Stéphane Culine
Journal:  Eur Urol       Date:  2007-09-04       Impact factor: 20.096

10.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.